Abdul Mannan: Managing Bleeding in Acquired Haemophilia A – Choosing the Right Haemostatic Strategy
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“In acquired haemophilia A, the best haemostatic agent depends on the patient in front of you.
Acquired haemophilia A is not the moment to admire a prolonged APTT from a distance.
If the patient is bleeding, act early and involve a haemophilia centre.
The new BSH/UKHCDO guideline keeps the message practical:
- Control bleeding first
- Avoid trauma and procedures where possible
- Use rFVIIa, aPCC/FEIBA, or rpFVIII for bleeding patients
- Monitor bypassing agents clinically, not by routine clotting tests
- Use rpFVIII when FVIII measurement can guide treatment
- Start inhibitor eradication with immunosuppression, tailored to risk
The key point?
BSH does not crown one universal winner between FEIBA, rFVIIa, and rpFVIII.
The right choice depends on the bleed, thrombotic risk, anti-porcine FVIII inhibitor status, lab support, access, and local haemophilia centre practice.
FEIBA/aPCC and rFVIIa remain trusted bypassing options. rpFVIII has the practical advantage of measurable FVIII levels, which can be very helpful when the bleeding is severe or the response is unclear.
AHA is rare, but when it appears, it tends to theatre. The platelet count sits there innocently while the APTT does all the shouting.
What drives your first choice in AHA bleeding: thrombosis risk, lab monitoring, local access, or centre protocol?”

Find more posts from Abdul Mannan on Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026